Table 2 Study endpoints by renal function strata
(A) Primary and secondary endpoints by renal function strata | |||||
Endpoint | Renal function | Placebo | Alogliptin | HR (95% CI) | Interactionpvalue |
Primary | eGFR ≥ 60 | 192 (9.8%) | 157 (7.9%) | 0.81 (0.65–0.99) | 0.014 |
eGFR < 60 | 124 (17.3%) | 148 (20.6%) | 1.20 (0.95–1.53) | ||
Secondary | eGFR ≥ 60 | 226 (11.5%) | 189 (9.5%) | 0.82 (0.68–0.99) | 0.021 |
eGFR < 60 | 133 (18.6%) | 155 (21.6%) | 1.17 (0.93–1.47) | ||
(B) Components of primary endpoint and other endpoints by renal function strata | |||||
Components of primary endpoint | Renal function | Placebo | Alogliptin | HR (95% CI) | Interactionpvalue |
CV death | eGFR ≥ 60 | 60 (3.1%) | 37 (1.9%) | 0.61 (0.41–0.92) | 0.079 |
eGFR < 60 | 51 (7.1%) | 52 (7.2%) | 1.01 (0.69–1.48) | ||
Non-fatal MI* | eGFR ≥ 60 | 113 (5.8%) | 99 (5%) | 0.86 (0.66–1.13) | 0.013 |
eGFR < 60 | 60 (8.4%) | 88 (12.3%) | 1.48 (1.07–2.06) | ||
Non-fatal stroke | eGFR ≥ 60 | 19 (1%) | 21 (1.1%) | 1.20 (0.95–1.53) | 0.28 |
eGFR < 60 | 13 (1.8%) | 8 (1.1%) | 0.61 (0.25–1.47) | ||
Other endpoints | Renal function | Placebo | Alogliptin | HR (95% CI) | Interactionpvalue |
All-cause death | eGFR ≥ 60 | 89 (4.5%) | 74 (3.7%) | 0.82 (0.60–1.12) | 0.56 |
eGFR < 60 | 84 (11.7%) | 79 (11.0%) | 0.93 (0.68–1.27) | ||
All CV deaths | eGFR ≥ 60 | 72 (3.7%) | 44 (2.2%) | 0.61 (0.42–0.88) | 0.013 |
eGFR < 60 | 58 (8.1%) | 68 (9.5%) | 1.16 (0.82–1.65) | ||
HF hospitalizations | eGFR ≥ 60 | 43 (2.2%) | 44 (2.2%) | 1.01 (0.67–1.55) | 0.32 |
eGFR < 60 | 46 (6.4%) | 62 (8.6%) | 1.35 (0.92–1.97) | ||